News Image

Does GENMAB A/S -SP ADR (NASDAQ:GMAB) match Peter Lynch’s “Invest in What You Know” philosophy?

By Mill Chart

Last update: Mar 28, 2025

Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether GENMAB A/S -SP ADR (NASDAQ:GMAB) fits the characteristics of a Lynch-approved investment.


Peter Lynch stocks image

Evaluating GENMAB A/S -SP ADR (NASDAQ:GMAB) using Peter Lynch’s legendary strategy

  • GMAB has achieved an impressive Return on Equity (ROE) of 21.38%, showcasing its ability to generate favorable returns for shareholders.
  • GMAB has a Debt/Equity ratio of 0.03, indicating a balanced approach to financing growth.
  • The 5-year EPS growth of GMAB (29.12) highlights the company's ability to consistently improve its earnings performance and suggests a positive outlook for future profitability.
  • With a PEG ratio of 0.39, GMAB presents a compelling case for growth at a fair price.
  • GMAB maintains a healthy liquidity position with a Current Ratio of 5.25.

What is the full fundamental picture of GMAB telling us.

As part of its analysis, ChartMill provides a comprehensive Fundamental Rating for each stock. This rating, ranging from 0 to 10, is updated on a daily basis and is based on the evaluation of various fundamental indicators and properties.

We assign a fundamental rating of 7 out of 10 to GMAB. GMAB was compared to 569 industry peers in the Biotechnology industry. GMAB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. GMAB is evaluated to be cheap and growing strongly. This does not happen too often! This makes GMAB very considerable for value and growth and quality investing!

Our latest full fundamental report of GMAB contains the most current fundamental analsysis.

More Affordable Growth stocks can be found in our Peter Lynch screener.

Keep in mind

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

GENMAB A/S -SP ADR

NASDAQ:GMAB (4/17/2025, 8:25:01 PM)

After market: 20.04 0 (0%)

20.04

+0.49 (+2.51%)



Find more stocks in the Stock Screener

GMAB Latest News and Analysis

ChartMill News Image2 days ago - ChartmillDespite its growth, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains within the realm of affordability.

GENMAB A/S -SP ADR was identified as a growth stock that isn't overvalued. NASDAQ:GMAB is excelling in various growth indicators while maintaining a solid financial footing.

Follow ChartMill for more